CN116983304A - Application of palmatine in preparing medicine for treating nasopharyngeal carcinoma - Google Patents
Application of palmatine in preparing medicine for treating nasopharyngeal carcinoma Download PDFInfo
- Publication number
- CN116983304A CN116983304A CN202310859699.6A CN202310859699A CN116983304A CN 116983304 A CN116983304 A CN 116983304A CN 202310859699 A CN202310859699 A CN 202310859699A CN 116983304 A CN116983304 A CN 116983304A
- Authority
- CN
- China
- Prior art keywords
- palmatine
- nasopharyngeal carcinoma
- cells
- treatment
- treating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010061306 Nasopharyngeal cancer Diseases 0.000 title claims abstract description 66
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 title claims abstract description 65
- 201000011216 nasopharynx carcinoma Diseases 0.000 title claims abstract description 65
- PTPHDVKWAYIFRX-UHFFFAOYSA-N Palmatine Natural products C1C2=C(OC)C(OC)=CC=C2C=C2N1CCC1=C2C=C(OC)C(OC)=C1 PTPHDVKWAYIFRX-UHFFFAOYSA-N 0.000 title claims abstract description 63
- QUCQEUCGKKTEBI-UHFFFAOYSA-N palmatine Chemical compound COC1=CC=C2C=C(C3=C(C=C(C(=C3)OC)OC)CC3)[N+]3=CC2=C1OC QUCQEUCGKKTEBI-UHFFFAOYSA-N 0.000 title claims abstract description 58
- 239000003814 drug Substances 0.000 title claims abstract description 15
- 238000002360 preparation method Methods 0.000 claims description 3
- 229940126585 therapeutic drug Drugs 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 2
- 230000001413 cellular effect Effects 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000000463 material Substances 0.000 claims description 2
- 239000007921 spray Substances 0.000 claims description 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 239000002552 dosage form Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 15
- 230000005012 migration Effects 0.000 abstract description 13
- 238000013508 migration Methods 0.000 abstract description 13
- 230000035755 proliferation Effects 0.000 abstract description 10
- 230000009545 invasion Effects 0.000 abstract description 8
- 230000002401 inhibitory effect Effects 0.000 abstract description 7
- 230000003833 cell viability Effects 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 229940093265 berberine Drugs 0.000 description 6
- QISXPYZVZJBNDM-UHFFFAOYSA-N berberine Natural products COc1ccc2C=C3N(Cc2c1OC)C=Cc4cc5OCOc5cc34 QISXPYZVZJBNDM-UHFFFAOYSA-N 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 230000004709 cell invasion Effects 0.000 description 5
- 230000001419 dependent effect Effects 0.000 description 5
- 239000012980 RPMI-1640 medium Substances 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 3
- 230000012292 cell migration Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- YBHILYKTIRIUTE-UHFFFAOYSA-N berberine Chemical compound C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 YBHILYKTIRIUTE-UHFFFAOYSA-N 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- FZAGOOYMTPGPGF-UHFFFAOYSA-N Lambertine Chemical compound C1=C2C3=CC4=CC=C(OC)C(OC)=C4CN3CCC2=CC2=C1OCO2 FZAGOOYMTPGPGF-UHFFFAOYSA-N 0.000 description 1
- 239000002841 Lewis acid Substances 0.000 description 1
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 150000007517 lewis acids Chemical class 0.000 description 1
- 108010082117 matrigel Proteins 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- NUJGJRNETVAIRJ-UHFFFAOYSA-N octanal Chemical compound CCCCCCCC=O NUJGJRNETVAIRJ-UHFFFAOYSA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000005760 tumorsuppression Effects 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses an application of palmatine in preparing a medicament for treating nasopharyngeal carcinoma. According to the invention, the Palmatine can obviously inhibit the activity of the nasopharyngeal carcinoma cells in a mode of inhibiting proliferation, migration and invasion of the nasopharyngeal carcinoma cells, so that the Palmatine can play a role in treating the nasopharyngeal carcinoma cells and inhibiting the migration of the nasopharyngeal carcinoma cells, and a new effective way is provided for treating the nasopharyngeal carcinoma.
Description
Technical Field
The invention belongs to the technical field of biological medicines, and particularly relates to application of palmatine in preparation of a nasopharyngeal carcinoma treatment drug.
Background
Nasopharyngeal carcinoma (NPC) is a malignant tumor of the head and neck. It has a very low incidence worldwide, but it is one of the most common malignant tumors in china. Although the local control rate of the nasopharyngeal carcinoma is obviously improved by the combined radiotherapy and chemotherapy, the 5-year survival rate of the nasopharyngeal carcinoma patients is still about 70% due to early metastasis and easy recurrence. Thus, there is an urgent need to study new therapeutic approaches.
For thousands of years, traditional Chinese Medicine (TCM) has been driving the development of Chinese and world medicine. At present, the traditional Chinese medicine is used as a substitute for treating malignant tumor or an auxiliary medicine to become a hot spot of clinical medical research, and the application of the traditional Chinese medicine in nasopharyngeal carcinoma treatment is one of the traditional Chinese medicine.
The Chinese patent application with publication number of CN101012227A discloses a novel 13-n-octyl berberine derivative with anti-tumor effect, wherein the novel 13-n-octyl berberine derivative is 13-n-octyl berberine (1) and 13-n-octyl palmatine (2):
the 13-n-octyl berberine and 13-n-octyl palmatine respectively take berberine and palmatine as raw materials, and the corresponding dihydro berberine and dihydro palmatine are respectively obtained through reduction; and then directly reacting with n-octyl aldehyde in ethanol under the action of weak acid or Lewis acid respectively, and heating for a period of time to reflux for hours to obtain the corresponding 13-n-octyl berberine and 13-n-octyl palmatine.
This technique shows that 13-n-octyl berberine and 13-n-octyl palmatine show superior tumor suppression (including S180 sarcoma) compared to berberine and palmatine due to the long carbon chain attached at position 13. However, no report that palmatine can treat nasopharyngeal carcinoma is currently seen.
Disclosure of Invention
The invention aims to provide the application of the palmatine in preparing the medicaments for treating the nasopharyngeal carcinoma, and provides a new effective way for treating the nasopharyngeal carcinoma.
In order to achieve the above purpose, the technical scheme of the invention is as follows:
the structural formula of the palmatine is shown as the formula (I):
according to the invention, the Palmatine can obviously inhibit the activity of the nasopharyngeal carcinoma cells in a mode of inhibiting proliferation, migration and invasion of the nasopharyngeal carcinoma cells, so that the Palmatine can play a role in treating the nasopharyngeal carcinoma cells and inhibiting the migration of the nasopharyngeal carcinoma cells, and a new effective way is provided for treating the nasopharyngeal carcinoma.
The research of the invention discovers that the palmatine IC for nasopharyngeal carcinoma cells 50 About 10 mu mol/L, thus ensuring that the amount of palmatine used at the cellular level is not less than 10 mu mol/L for optimal therapeutic effect.
The invention also provides a nasopharyngeal carcinoma therapeutic drug which at least comprises palmatine and pharmaceutically acceptable auxiliary materials.
The preparation formulation of the nasopharyngeal carcinoma therapeutic drug can comprise spray, oral administration agent, capsule, tablet or injection.
Compared with the prior art, the invention has the beneficial effects that:
according to the invention, the Palmatine can obviously inhibit the activity of the nasopharyngeal carcinoma cells in a mode of inhibiting proliferation, migration and invasion of the nasopharyngeal carcinoma cells, so that the Palmatine can play a role in treating the nasopharyngeal carcinoma cells and inhibiting the migration of the nasopharyngeal carcinoma cells, and a new effective way is provided for treating the nasopharyngeal carcinoma.
Drawings
FIG. 1 is a graph showing the effect of treatment with palmatine at various concentrations on nasopharyngeal carcinoma cell viability;
in the figure, relative cell viability (%) indicates relative cell viability (percent), control indicates negative Control (cells not treated with palmatine), and palmatine-L/M/H indicates treatment of cells with low (2.5. Mu. Mol/L)/medium (5. Mu. Mol/L)/high (10. Mu. Mol/L). * p<0.05， ** p<0.01， *** p<0.001vs. control; the following is the same; FIG. 2 shows proliferation of nasopharyngeal carcinoma cells treated with various concentrations of palmatine;
FIG. 3 is a graph showing the effect of different concentrations of palmatine treatment on proliferation of nasopharyngeal carcinoma cells;
in the figure, relative colony numbers (%) represents the relative clone number (percent);
FIG. 4 shows migration of nasopharyngeal carcinoma cells after treatment with various concentrations of palmatine;
FIG. 5 is a graph showing the effect of different concentrations of palmatine treatment on nasopharyngeal carcinoma cell migration;
wherein Relative migration rates (%) represents relative mobility (percent);
FIG. 6 shows the invasion of nasopharyngeal carcinoma cells after various concentrations of palmatine treatment;
FIG. 7 is the effect of different concentrations of palmatine treatment on nasopharyngeal carcinoma cell invasion;
wherein Relative invasion rates (%) represents the relative attack rate (percent);
FIG. 8 is a graph showing the effect of different concentrations of palmatine treatment on nasopharyngeal carcinoma cell phenotype.
Detailed Description
The technical scheme of the invention is further described in detail below with reference to the attached drawings and the detailed description.
Example 1 Effect of different concentrations of palmatine treatment on nasopharyngeal carcinoma cell viability
To analyze the effect of palmatine on nasopharyngeal carcinoma cell viability, this example was performed at 90%
Nasopharyngeal carcinoma (NPC) cells C666-1 and HK1 were cultured in RPMI-1640+10% FBS medium for 48h, and then treated with palmatine (0,2.5,5 and 10. Mu. Mol/L) at different concentrations for 24 h; finally, detecting the cell viability by using an MTT kit, and detecting at 490nm absorbance by using an enzyme-labeled instrument, wherein the detection result is shown in figure 1.
As can be seen from FIG. 1, as the palmatine treatment concentration was increased gradually, the viability of both C666-1 and HK1 cells decreased gradually; at 10. Mu. Mol/L, an inhibition of about 50% was achieved; it can be seen that palmatine significantly inhibited NPC cell viability in a concentration-dependent manner.
Example 2 Effect of different concentrations of palmatine treatment on proliferation of nasopharyngeal carcinoma cells
The influence of different concentrations of palmatine treatment on proliferation of nasopharyngeal carcinoma cells is analyzed by adopting a clone formation test, and the specific method comprises the following steps:
in this example, nasopharyngeal carcinoma (NPC) cells C666-1 and HK1 were first cultured in 90% RPMI-1640+10% FBS medium for 48h, then cells were treated with different concentrations of palmatine (0,2.5,5 and 10. Mu. Mol/L), and the palmatine and cells were incubated at 37℃for 14 days; cells were then fixed with 4% paraformaldehyde and stained with 0.5% crystal violet solution. Finally, the cell proliferation was observed by an inverted microscope, and the observation results and analysis results are shown in fig. 2 and 3.
As can be seen from FIGS. 2 and 3, as the concentration of palmatine treatment increases gradually, the proliferation capacities of C666-1 and HK1 cells decrease gradually, the inhibition rate of proliferation of C666-1 cells reaches about 50% at 5. Mu. Mol/L, and the inhibition rate of proliferation of HK1 cells reaches about 75%; it can be seen that palmatine significantly inhibited nasopharyngeal carcinoma cell proliferation in a concentration-dependent manner.
Example 3 Effect of different concentrations of palmatine treatment on nasopharyngeal cancer cell migration
The embodiment adopts a wound healing experiment to analyze the influence of different concentrations of palmatine treatment on the migration of nasopharyngeal carcinoma cells, and the specific method comprises the following steps:
cells of C666-1 and HK1 were seeded in 6-well plates and incubated overnight until 80-90% confluence occurred, and the next day, streaked on the cells with a pipette and the floating cells were washed away. After further culturing in serum-free cell culture medium for 24 hours, the migration of cells was observed with an inverted microscope, and the observation results and analysis results are shown in fig. 4 and 5, respectively.
As can be seen from FIGS. 4 and 5, as the concentration of palmatine treatment increases gradually, the migration ability of C666-1 and HK1 cells decreases gradually, the inhibition rate of migration of C666-1 cells reaches below 50% at 5. Mu. Mol/L, and the inhibition rate of migration of HK1 cells reaches about 50%; it can be seen that palmatine significantly inhibited NPC cell migration in a concentration-dependent manner.
Example 4 Effect of different concentrations of palmatine treatment on nasopharyngeal carcinoma cell invasion
The embodiment adopts a Transwell test to analyze the influence of different concentrations of palmatine treatment on nasopharyngeal carcinoma cell invasion, and the specific method comprises the following steps:
nasopharyngeal carcinoma (NPC) cells C666-1 and HK1 were first cultured in 90% RPMI-1640+10% FBS medium for 48h, and then cells were treated with different concentrations of palmatine (0,2.5,5 and 10. Mu. Mol/L) for 24 h; the upper chamber of the Transwell chamber was coated with matrigel, NPC cells after palmatine treatment were inoculated into the Transwell upper chamber, complete medium containing 10% FBS was added to the lower chamber, after 48 hours of culture, the lower Transwell chamber was fixed with 4% paraformaldehyde, stained with crystal violet, and observed for cell invasion under an inverted optical microscope (Eclipse Ts2, nikon, japan), and the observation results and analysis results are shown in fig. 6 and 7, respectively.
As can be seen from FIGS. 6 and 7, as the palmatine treatment concentration gradually increased, the invasion capacity of C666-1 and HK1 cells gradually decreased, the inhibition rate of invasion of C666-1 cells reached about 50% at 5. Mu. Mol/L, and the inhibition rate of invasion of HK1 cells reached about 80% at 10. Mu. Mol/L; it can be seen that palmatine significantly inhibited NPC cell invasion in a concentration-dependent manner.
Example 5 Effect of different concentrations of palmatine treatment on nasopharyngeal carcinoma cell phenotype
To analyze the effect of different concentrations of palmatine treatment on nasopharyngeal carcinoma cell phenotype, this example first cultures nasopharyngeal carcinoma (NPC) cells C666-1 and HK148h in 90% RPMI-1640+10% FBS medium, and then treats the cells with different concentrations of palmatine (0,2.5,5 and 10 μmol/L) for 24 hours; the cell lines were then examined under a microscope for phenotypic changes and the observations are shown in figure 8.
As can be seen from FIG. 8, palmatine is a concentration-dependent reversal of the CCC6-1 and HK-1 cell mesenchymal phenotypes, indicating that palmatine is effective in inhibiting infiltration metastasis of nasopharyngeal carcinoma.
Claims (6)
1. Application of palmatine in preparing medicine for treating nasopharyngeal carcinoma is provided.
2. The use according to claim 1, wherein the structural formula of palmatine is as shown in formula (i):
3. the use according to claim 1, wherein the amount of palmatine used is not less than 10 μmol/L at the cellular level.
4. The nasopharyngeal carcinoma therapeutic drug is characterized by at least comprising palmatine and pharmaceutically acceptable auxiliary materials.
5. The therapeutic agent for nasopharyngeal carcinoma according to claim 4, wherein the structural formula of palmatine is represented by formula (i):
6. the therapeutic agent for nasopharyngeal carcinoma as set forth in claim 4, wherein the dosage form comprises a spray, an oral preparation, a capsule, a tablet, or an injection.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310859699.6A CN116983304A (en) | 2023-07-13 | 2023-07-13 | Application of palmatine in preparing medicine for treating nasopharyngeal carcinoma |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310859699.6A CN116983304A (en) | 2023-07-13 | 2023-07-13 | Application of palmatine in preparing medicine for treating nasopharyngeal carcinoma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116983304A true CN116983304A (en) | 2023-11-03 |
Family
ID=88531247
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310859699.6A Pending CN116983304A (en) | 2023-07-13 | 2023-07-13 | Application of palmatine in preparing medicine for treating nasopharyngeal carcinoma |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116983304A (en) |
-
2023
- 2023-07-13 CN CN202310859699.6A patent/CN116983304A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111420030A (en) | Application of FGF21 in preparation of medicine for treating colorectal cancer | |
| CN107778362B (en) | Polypeptide for inhibiting migration and invasion capacity of oral squamous cell carcinoma and application thereof | |
| JP2019504894A (en) | Use of the PDE4 inhibitor ZL-n-91 in the preparation of drugs for lung cancer growth and metastasis | |
| CN111617249A (en) | Application of hsa _ circ _0007444 in preparation of medicine for treating ovarian cancer | |
| CN116983304A (en) | Application of palmatine in preparing medicine for treating nasopharyngeal carcinoma | |
| CN109200041B (en) | Application of cyperus azulene ketone in preparing medicine for treating esophageal squamous cell carcinoma by inhibiting SIRT1 gene expression | |
| CN108295085B (en) | Application of protodioscin in preparation of drug-resistant osteosarcoma drug | |
| CN113876763B (en) | Application of hispidulin in preparation of anti-bile duct cancer drugs | |
| CN113440519A (en) | Application of mycophenolic acid and derivatives thereof in preparation of drugs for targeted therapy of cancers | |
| CN110283825B (en) | SiRNA capable of knocking down SRC-1 gene expression and application thereof | |
| CN113995753A (en) | Application of Chinese medicinal molecular sophocarpine in preparing medicament for treating glioblastoma | |
| CN115212199A (en) | Application of small molecular compound in preparation of medicine for treating diffuse large B cell lymphoma | |
| CN114989234A (en) | Preparation method and application of iridoid glycoside compound C in dogwood | |
| CN106075454A (en) | A kind of anti-tumor medicinal preparation combination | |
| CN111374979A (en) | Medical application of compound in treatment of oral cancer by inducing apoptosis of oral cancer cells | |
| CN113908148B (en) | Application of nobiletin in preparation of anti-cholangiocarcinoma drugs | |
| CN111170980A (en) | Calycosin derivative and synthesis method and application thereof | |
| CN113925850B (en) | Use of D-mannose in combination with PD-1 antibodies in the preparation of a medicament for the treatment of triple negative breast cancer | |
| CN117357543B (en) | Application of Sequiside L in breast cancer treatment | |
| CN116850190B (en) | Application of Dorsomorphin in preparation of medicines for treating bladder cancer | |
| CN111419837B (en) | Use of 12 alpha-methoxy-germacrane-triene-12, 6 alpha-acetal for anti-human rhabdomyosarcoma | |
| CN110151976B (en) | Application of ZNF496 protein in improving sensitivity of cervical cancer chemotherapy drugs | |
| CN109061188B (en) | Application of ERBB4 in gastric cancer treatment | |
| CN116814625A (en) | Mimic-QHSC-miRNA for preventing and/or treating hepatocellular carcinoma and application thereof | |
| CN117771254A (en) | And bufalin application in preparation of medicines for treating colorectal cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |